Jin Medical International (ZJYL) Common Equity (2022 - 2025)

Jin Medical International (ZJYL) has reported Common Equity for 4 consecutive years, with $29.6 million the latest figure, recorded in Q3 2025.

• Quarterly Common Equity rose 2.86% year-over-year to $29.6 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $29.6 million (up 2.86% YoY) and the FY2025 annual result came in at $29.6 million, up 2.86% from the prior year.
• Common Equity climbed to $29.6 million in Q3 2025 per ZJYL's latest filing, from $27.8 million in the prior quarter.
• Over the last five years, Common Equity for ZJYL reached as high as $29.6 million in Q3 2025 and fell as low as $15.2 million in Q3 2022.
• A 4-year average of $25.0 million and a median of $26.2 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity soared 57.39% — and 2025, when it increased 2.86%.
• Year by year, Common Equity stood at $15.2 million in 2022, then soared by 57.39% to $24.0 million in 2023, then gained by 20.17% to $28.8 million in 2024, then rose by 2.86% to $29.6 million in 2025.
• According to Business Quant data, Common Equity over the past three periods registered $29.6 million, $27.8 million, and $28.8 million for Q3 2025, Q1 2025, and Q3 2024 respectively.